White Blood Cell Growth Factors
Key Points
Key Points
Primary prophylaxis is recommended for the prevention of febrile neutropenia in patients who are at high risk on the basis of age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen.
Dose-dense regimens that require CSFs should be used only within an appropriately designed clinical trial or if supported by convincing efficacy data.
Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.
Diagnosis
Diagnos...
...Risk Factors for Febrile Neutropenia ...
...le 2. Patient Risk Factors for Poo...
Treatment for Adult Patients
...tment for Adult Patie...
...phylaxis with a CSF starting with the first...
...hylaxis with a CSF is recommended for patients...
...t be routinely used for patients with n...
...should not be routinely used as adjunctive trea...
...cer and lymphoma] ( EB , H , B , S )3...
...or urothelial cancer] ( EB , I , B...
...used alone, after chemotherapy, or in combinat...
...e administered after autologous stem-cell trans...
...may be administered after allogeneic stem-cell...
...actic CSFs for patients with diffuse ag...
...rastim, filgrastim, tbo-filgrastim, and fi...
...ndations for the management of patients expos...
Treatment for Pediatric Patients
...for Pediatric Patients...
...CSFs in pediatric patients will almost...
...indications in which dose-intense chemotherapy...
...not be used in pediatric patients with...
Table 3. Dosing and Administration of CSFs
Table 3. Dosing and Administration of CSFsH...